Publicaciones en colaboración con investigadores/as de Kiel University (10)

2021

  1. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

2018

  1. Automated database-guided expert-supervised orientation for immunophenotypic diagnosis and classification of acute leukemia

    Leukemia, Vol. 32, Núm. 4, pp. 874-881

2016

  1. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

    The Lancet Haematology, Vol. 3, Núm. 11, pp. e506-e515

2015

  1. Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers

    Genome Research, Vol. 25, Núm. 4, pp. 478-487

  2. Whole-genome fingerprint of the DNA methylome during human B cell differentiation

    Nature Genetics, Vol. 47, Núm. 7, pp. 746-756

2014

  1. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1195-1206

2013

  1. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma

    Journal of Clinical Oncology

2011

  1. Personalized therapy in multiple myeloma according to patient age and vulnerability: A report of the European Myeloma Network (EMN)

    Blood, Vol. 118, Núm. 17, pp. 4519-4529

2009

  1. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia

    Cancer Research, Vol. 69, Núm. 10, pp. 4443-4453

  2. Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma

    CLINICAL LYMPHOMA & MYELOMA